ClinicalTrials.gg
RecruitingNCT05913947DUAG9Updated Oct 29, 2026

Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)

A Phase 4 interventional study of Lithium and Cariprazine in Depression, Bipolar, sponsored by Aalborg University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Aalborg University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2022, registered Mar 2023).
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies testing lithium in Bipolar Disorder — 1 open to participants now, 1 under way, none of them phase 3. Lithium · Bipolar Disorder.

Planned enrollment
9th of 37
122 · median 49
Started
2022
the only one that year
Phase 4
16 of 37
1 open now
Registered
37th of 37
by date
Lead sponsor
1 of 37
Aalborg University Hospital

Among the 37 studies testing lithium in Bipolar Disorder, this one is the 9th largest by planned enrollment, is the only one that started in 2022, is one of 16 in phase 4, and was the 37th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

1 of the 37 studies testing lithium in Bipolar Disorder is open now, in 1 country.

By country, each count listing its studies:

About lithium

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing lithium in Bipolar Disorder, or all of them as a file.
02

Study summary

The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease.

The main question it aims to answer is:

Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6)

Participants will be randomized to treatment with either lithium or cariprazin.

  • Will meet for interview and ratings 4 times during study period.
  • In two meetings, there will be made blood samples and ECG. At one meeting also a Urine sample.
  • Will be contacted for telephone interviews at 6 occasions.
Read the detailed description

The primary aim is to investigate whether cariprazine is superior to lithium or vice versa in the acute treatment of patients with bipolar type 1 or 2 in a current depressive episode measured as change on the Hamilton Depression Scale, 6 item version (HDS-6) from baseline to 8 weeks of treatment. Secondarily, we aimed at comparing the two study medications on various other clinically relevant variables.

These include depressive and manic symptomatology, sleep patterns, general well-being, cognitive function, social functioning and suicidal ideation.

03

Conditions studied

  • Depression, Bipolar

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of bipolar disorder, type 1 or type 2, and a current episode of depression according to
  • Severity of depression: A score of at least 21 on the self-reported Major Depression Inventory (MDI).
  • No start or dose increase of psychotropic medication (except for benzodiazepines and benzodiazepine-like drugs (zopiclone, zolpidem, and melatonin)) in the two weeks prior to inclusion.
  • No new start of formalized psychotherapy sessions, excluding psychoeducation, during the 4 weeks prior to inclusion.
  • Age criteria: Subjects must be at least 18 years old and below 65 at the time of randomization.
  • The duration of the current depressive episode must be between 4 and 52 weeks as judged by the investigator at the time of randomization.
  • Clinical uncertainty regarding which of the alternatives, cariprazine and lithium, would be the better choice in the specific case.
  • Female participants should be sterile or non-fertile or, in case of being fertile, they must have a negative pregnancy test AND use safe anticonception.
  • Signed document of .

Exclusion criteria

Exclusion Criteria:

  • Prior or ongoing acute treatment of a depressive episode lasting > 14 days with either lithium or cariprazine as judged by the investigator.
  • ECT within the current depressive episode.
  • A score of MAS > 6.
  • A diagnosis of dementia.
  • High risk of non-adherence at the investigator's discretion.
  • Not understanding the Danish language as judged by the investigator
  • Psychiatric coercion in the form of forced admission or detainment OR sentence to forensic psychiatric care.
  • Presence of delusions, hallucinations or other psychotic symptoms as judged by the investigator.
  • Suicidality according to C-SSRS with a positive response to question 4 or 5 or upon investigator's discretion.
  • Medical conditions like cancer, kidney failure, epilepsy, deep brain stimulation device, or other medical conditions interfering with study the outcome and safety as judged by investigator's discretion.
  • Current harmful use or dependency of alcohol or drugs according to .
  • Known allergy to any of the substances in the study medication.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Experimental
    Lithium

    Lithium citrate from 12 mmol increased to result in af 12-hour se-lithium between 0.6 and 0.8 mmol/l

    Drug: Lithium

  • Experimental
    Cariprazine

    Cariprazine from 1.5 mg to 3 mg daily in a single dose.

    Drug: Cariprazine

Interventions

  • The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.

    Also known as: Litarex, ATC; N05AN01

  • The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.

    Also known as: Reagila, ATC: N05AX15

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depressions scale, version 6 (HDS-6)

    The primary aim is to investigate whether cariprazine is superior to lithium or vice versa in the acute treatment of patients with bipolar type 1 or 2 in a current depressive episode measured as change on the Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).

    Time frame: 8 weeks

Secondary outcomes

  1. Difference-in-difference for HDS-17

    Difference-in-differences for secondary continuous measures: Hamilton Depression Scale, 17 item version, HDS-17. (Values 0- 52, higher scores mean a worse outcome)

    Time frame: Week 4 and 8

  2. Difference-in-differences in HDS-6 for the PP 8 population

    Difference-in-differences (baseline to 8 weeks) in HDS-6 for the PP 8 population. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).

    Time frame: 8 weeks

  3. Between-groups difference in proportion of responders and remitters in HDS-6 Scores.

    Between-groups difference in proportion of responders and remitters at week 4 and 8 in HDS-6 scores. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).

    Time frame: Week 4 and week 8

  4. Between-groups difference in proportion of responders and remitters

    Between-groups difference in proportion of responders and remitters with response and remission defined by HDS-6 score without clinical relevant manic symptoms (MAS \<7) at planned or premature endpoint. Hamilton Depression Scale, 6 item version, HDS-6. (Values 0- 22, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  5. Between-groups difference in the proportion of patients with 'acceptable wellbeing'

    Between-groups difference in the proportion of patients with 'acceptable wellbeing', defined as the subject reporting ≥50 on the WHO-5 questionnaire at endpoint. WHO-five Well-being Index, WHO-5 (Values 0- 100, higher scores mean a better outcome).

    Time frame: up to 8 weeks

  6. Between-groups difference in proportion of switches to mania/hypomania.

    Between-groups difference in proportion of switches to mania/hypomania with or without mixed features, defined as mania/hypomania after DSM-5 or symptoms requiring treatment (switch or response occurring at any time in the study period)

    Time frame: up to 8 weeks

  7. Between-groups difference in "(switch to mania or hypomania) / (response) -ratio",

    Between-groups difference in "(switch to mania or hypomania) / (response) -ratio", defined as the number of subjects switching to mania or hypomania (as defined above) divided by the total number of responders, including those responders switching to mania

    Time frame: up to 8 weeks

  8. Between-group differences in reason for and time to all cause treatment discontinuation

    Between-group differences in reason for and time to all cause treatment discontinuation (lack of effect, lack of tolerability, lost to follow-up, or other cause).

    Time frame: up to 8 weeks

  9. Between-group difference in treatment compliance.

    Between-group difference in treatment compliance. Treatment compliance is defined as the proportion of received treatments out of the planned until drop-out or end of study.

    Time frame: up to 8 weeks

  10. Between-group difference in reasons for premature discontinuation

    Between-group difference for the ITT population in reasons for premature discontinuation

    Time frame: up to 8 weeks

  11. Difference-in-difference for MAS

    Difference-in-differences for secondary continuous measures: MAS Bech-Rafaelsens Mania scale .(Values 0- 44, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  12. Difference-in-difference for MES

    Difference-in-differences for secondary continuous measures: MES Bech-Rafaelsens Melancholia scale, MES .(Values 0- 44, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  13. Difference-in-differences for MADRS

    Difference-in-differences for secondary continuous measures: MADRS Montgomery-Aaberg Depression Rating Scale, MADRS .(Values 0- 60, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  14. Difference-in-difference for YMRS

    Difference-in-differences for secondary continuous measures:YMRS Young Mania Rating Scale, YMRS .(Values 0- 60, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  15. Difference-in-differences for ASRM-14

    Difference-in-differences for secondary continuous measures:ASRM-14 Altman Self-Rating Mania Scale-14, .(Values 0- 56, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  16. Difference-in-differences for MDI

    Difference-in-differences for secondary continuous measures:MDI Major Depression Inventory, MDI (Values 0- 58, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  17. Difference-in-differences for WHO-5 questionnaire

    Difference-in-differences for secondary continuous measures: WHO-5 questionnaire. WHO-five Well-beeing Index, WHO-5 (Values 0- 100, higher scores mean a better outcome).

    Time frame: Week 4 and 8

  18. Difference-in-difference for SCIP

    Difference-in-differences for secondary continuous measures: SCIP Screen for Cognitive Impairment in Psychiatry, SCIP (Values 0- 64+, higher scores mean a better outcome)

    Time frame: Week 8

  19. Difference-in-difference for COBRA

    Difference-in-differences for secondary continuous measures: COBRA Cognitive complaints in bipolar disorder Ratings assessment, COBRA, (Values 0- 48, higher scores mean a worse outcome).

    Time frame: Week 8

  20. Difference-in-difference for FAST

    Difference-in-differences for secondary continuous measures: FAST Functioning Assessment Short Test, FAST (Values 0 - 72, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  21. Difference-in-difference for PSQI

    Difference-in-differences for secondary continuous measures:PSQI PIttsburgh Sleep Quality Index, PSQI (Values 0 - 21, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  22. Difference-in-difference for CGI-S

    Difference-in-differences for secondary continuous measures: CGI-S Clinical Global Impression Scale - Severity, CGI-S (Values 1 -7, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  23. Difference-in-difference for CGI-I

    Difference-in-differences for secondary continuous measures:CGI-I Clinical Global Impression Scale - Global Improvement CGI- I (Values 1 -7, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  24. Difference-in-difference for C-SSRS

    Difference-in-differences for secondary continuous measures: C-SSRS Columbia-Suicide Severity Rating Scale, C-SSRS (Values 1 - 5, higher scores mean a worse outcome).

    Time frame: Week 4 and 8

  25. Difference-in-difference for accumulated benzodiazepine dose

    Difference-in-differences for secondary continuous measures: accumulated benzodiazepine dose as diazepam equivalents (DSKP)

    Time frame: Up to 8 weeks

  26. Difference-in-difference for time to all-causes discontinuation

    Difference-in-differences for secondary continuous measures: for time to all-causes discontinuation

    Time frame: Up to 8 weeks

  27. Difference-in-difference for time to all-causes. all-causes study endpoint.

    Difference-in-differences for secondary continuous measures: all-causes study endpoint.

    Time frame: Up to 8 weeks

  28. Between-group difference in reasons for time to all cause discontinuation.

    Between-group difference for the ITT population in reasons for time to all cause discontinuation.

    Time frame: Up to 8 weeks

  29. Between-group difference in reasons for treatment expectation.

    Between-group difference for the ITT population in reasons for treatment expectation.

    Time frame: Up to 8 weeks

  30. Between-group difference in reasons for adverse events.

    Between-group difference for the ITT population in reasons for adverse events.

    Time frame: Up to 8 weeks

  31. Between-group difference in reasons for serious adverse events.

    Between-group difference for the ITT population in reasons for serious adverse events.

    Time frame: Up to 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hovgesen SV, Licht RWW, Straszek SPV, Christensen AE, Vinberg M, Videbech P, Miskowiak KW, Johnsen S, Munk MM, Mai ML, Baethge C, Kessing LV, Nielsen RE. Lithium versus cariprazine in the acute phase treatment for depressive episodes in patients with bipolar disorder: a protocol for a pragmatic open, randomised multicentre study - the 9th trial of the Danish University Antidepressant Group, DUAG-9. BMJ Open. 2025 Aug 27;15(8):e102406. doi: 10.1136/bmjopen-2025-102406. PubMed 40866064 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Sep 2028, 68 months after the start.

Of 39 non-industry phase 4 interventional studies under Bipolar Disorder, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 68 months is above that.

Counting every sponsor, half of 44 studies reached it within 43 months; a quarter within 25 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Jun 22, 2023
StartActual
Dec 13, 2022
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 2, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05913947
Collaborators
Glostrup University Hospital, Copenhagen, Mental Health Department Odense, University Clinic, Psychiatric Center Copenhagen, Rigshospitalet, Psychiatric Hospital, Hillerod
Responsible party
René Ernst Nielsen (MD, PhD, Professor, Aalborg University Hospital) — Principal investigator
First posted
Jun 22, 2023
Start date
Dec 13, 2022
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 2, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Sanne V. Hovgesen, MD
Contact
sanne.hovgesen@rn.dk
+45 25487706
Simon Johnsen, MsN
Contact
simonjohnsen@rn.dk
+45 50589034
René E. Nielsen, Prof, MD,PhD
principal investigator · Psychiatry, Aalborg University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lithium · Cariprazine

Start the discussion